Kehua Biotech announced that Kehua Bioengineering Co., Ltd., a wholly-owned subsidiary of the company, recently received a medical device registration certificate from the Shaanxi Drug Administration, involving 3 products: an antithyroglobulin antibody test kit, a tumor-related antigen CA125 test kit, and a beta human chorionic gonadotropin test kit. The registration certificates are all valid from September 21, 2026 to September 20, 2031.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.